Bromodomains: a new target class for small molecule drug discovery

[1]  James M. Woolven,et al.  Fragment-based discovery of bromodomain inhibitors part 1: inhibitor binding modes and implications for lead discovery. , 2012, Journal of medicinal chemistry.

[2]  David M. Wilson,et al.  Fragment-based discovery of bromodomain inhibitors part 2: optimization of phenylisoxazole sulfonamides. , 2012, Journal of medicinal chemistry.

[3]  S. Robson,et al.  Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia , 2011, Nature.

[4]  S. Lowe,et al.  RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia , 2011, Nature.

[5]  S. Knapp,et al.  Bromodomain-peptide displacement assays for interactome mapping and inhibitor discovery. , 2011, Molecular bioSystems.

[6]  P. Sandy,et al.  Targeting MYC dependence in cancer by inhibiting BET bromodomains , 2011, Proceedings of the National Academy of Sciences.

[7]  R. Young,et al.  BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc , 2011, Cell.

[8]  S. Knapp,et al.  3,5-Dimethylisoxazoles Act As Acetyl-lysine-mimetic Bromodomain Ligands , 2011, Journal of medicinal chemistry.

[9]  C. Musselman,et al.  Handpicking epigenetic marks with PHD fingers , 2011, Nucleic acids research.

[10]  G. Otterson,et al.  Romidepsin: a novel histone deacetylase inhibitor for cancer , 2011, Expert opinion on investigational drugs.

[11]  W. Parson,et al.  Inhibition of the Acetyltransferases p300 and CBP Reveals a Targetable Function for p300 in the Survival and Invasion Pathways of Prostate Cancer Cell Lines , 2011, Molecular Cancer Therapeutics.

[12]  P. Bamborough,et al.  Discovery and characterization of small molecule inhibitors of the BET family bromodomains. , 2011, Journal of medicinal chemistry.

[13]  Jennifer A. Smith,et al.  The Brd4 Extraterminal Domain Confers Transcription Activation Independent of pTEFb by Recruiting Multiple Proteins, Including NSD3 , 2011, Molecular and Cellular Biology.

[14]  Ming-Ming Zhou,et al.  A small molecule binding to the coactivator CREB-binding protein blocks apoptosis in cardiomyocytes. , 2011, Chemistry & biology.

[15]  T. Umehara,et al.  Real-time imaging of histone H4K12-specific acetylation determines the modes of action of histone deacetylase and bromodomain inhibitors. , 2011, Chemistry & biology.

[16]  B. Pollock,et al.  Multilocus Association of Genetic Variants in MLL, CREBBP, EP300, and TOP2A with Childhood Acute Lymphoblastic Leukemia in Hispanics from Texas , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[17]  J. Kastelein,et al.  Lipid parameters for measuring risk of cardiovascular disease , 2011, Nature Reviews Cardiology.

[18]  M. Brown,et al.  Whole blood transcriptional profiling in ankylosing spondylitis identifies novel candidate genes that might contribute to the inflammatory and tissue-destructive disease aspects , 2011, Arthritis Research & Therapy.

[19]  S. Minucci,et al.  Next generation histone deacetylase inhibitors: the answer to the search for optimized epigenetic therapies? , 2011, Expert opinion on drug discovery.

[20]  Kenneth H. Buetow,et al.  CREBBP mutations in relapsed acute lymphoblastic leukaemia , 2011, Nature.

[21]  P. Grandi,et al.  Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes , 2011, Nature Biotechnology.

[22]  A. Singer,et al.  Chromatin remodeling complex NURF regulates thymocyte maturation. , 2011, Genes & development.

[23]  J. Krebs,et al.  WSTF does it all: a multifunctional protein in transcription, repair, and replication. , 2011, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[24]  W. Wood,et al.  Dynamic BRG1 Recruitment during T Helper Differentiation and Activation Reveals Distal Regulatory Elements , 2011, Molecular and Cellular Biology.

[25]  D. Grozeva,et al.  Most genome-wide significant susceptibility loci for schizophrenia and bipolar disorder reported to date cross-traditional diagnostic boundaries. , 2011, Human molecular genetics.

[26]  C. Rice,et al.  Suppression of inflammation by a synthetic histone mimic , 2010, Nature.

[27]  Eric Boerwinkle,et al.  Genome-wide association study identifies novel loci for plasma levels of protein C: the ARIC study , 2022 .

[28]  V. Mohan,et al.  Replication of recently described type 2 diabetes gene variants in a South Indian population. , 2010, Metabolism: clinical and experimental.

[29]  G. Denis.  Bromodomain coactivators in cancer, obesity, type 2 diabetes, and inflammation. , 2010, Discovery medicine.

[30]  Tariq Ahmad,et al.  Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci , 2010, Nature Genetics.

[31]  J. Ferralli,et al.  ATAD2B is a phylogenetically conserved nuclear protein expressed during neuronal differentiation and tumorigenesis , 2010, Development, growth & differentiation.

[32]  P. A. Futreal,et al.  Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma , 2010, Nature.

[33]  R. Cardiff,et al.  ANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of B-Myb and EZH2. , 2010, Cancer research.

[34]  S. Sugayama,et al.  Evaluation of the immune humoral response of Brazilian patients with Rubinstein-Taybi syndrome. , 2010, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[35]  A. Zwinderman,et al.  Genetic variation in PCAF, a key mediator in epigenetics, is associated with reduced vascular morbidity and mortality: evidence for a new concept from three independent prospective studies , 2010, Heart.

[36]  C. Wijmenga,et al.  Exploring genetic determinants of plasma total cholesterol levels and their predictive value in a longitudinal study. , 2010, Atherosclerosis.

[37]  D. Patel,et al.  TRIM24 links a noncanonical histone signature to breast cancer , 2010, Nature.

[38]  William B. Smith,et al.  Selective inhibition of BET bromodomains , 2010, Nature.

[39]  A. Revenko,et al.  Chromatin Loading of E2F-MLL Complex by Cancer-Associated Coregulator ANCCA via Reading a Specific Histone Mark , 2010, Molecular and Cellular Biology.

[40]  H. Kimura,et al.  Oncogenesis by sequestration of CBP/p300 in transcriptionally inactive hyperacetylated chromatin domains , 2010, The EMBO journal.

[41]  M. Martinka,et al.  BRG1 expression is increased in human cutaneous melanoma , 2010, The British journal of dermatology.

[42]  R. Elkon,et al.  BRD7 is a candidate tumour suppressor gene required for p53 function , 2010, Nature Cell Biology.

[43]  Shalom Madar,et al.  A Novel Translocation Breakpoint within the BPTF Gene Is Associated with a Pre-Malignant Phenotype , 2010, PloS one.

[44]  Dimitris Thanos,et al.  The transcriptional code of human IFN-beta gene expression. , 2010, Biochimica et biophysica acta.

[45]  Y. Toiyama,et al.  KAP1 Is Associated With Peritoneal Carcinomatosis in Gastric Cancer , 2010, Annals of Surgical Oncology.

[46]  Ivan Dikic,et al.  Ubiquitin ligase complexes: from substrate selectivity to conjugational specificity , 2010, Biological chemistry.

[47]  R. Siebert,et al.  Germline nonsense mutation and somatic inactivation of SMARCA4/BRG1 in a family with rhabdoid tumor predisposition syndrome. , 2010, American journal of human genetics.

[48]  C. Musselman,et al.  PHD fingers: epigenetic effectors and potential drug targets. , 2009, Molecular interventions.

[49]  Lars Alfredsson,et al.  Specific interaction between genotype, smoking and autoimmunity to citrullinated α-enolase in the etiology of rheumatoid arthritis , 2009, Nature Genetics.

[50]  K. Helin,et al.  ATAD2 is a novel cofactor for MYC, overexpressed and amplified in aggressive tumors. , 2009, Cancer research.

[51]  Manel Esteller,et al.  Epigenetic mechanisms in neurological diseases: genes, syndromes, and therapies , 2009, The Lancet Neurology.

[52]  J. Mackay,et al.  It takes two to tango: the structure and function of LIM, RING, PHD and MYND domains. , 2009, Current pharmaceutical design.

[53]  Wolfgang Sippl,et al.  The Emerging Therapeutic Potential of Histone Methyltransferase and Demethylase Inhibitors , 2009, ChemMedChem.

[54]  D. Chua,et al.  Characterization of tumor suppressive function of P300/CBP-associated factor at frequently deleted region 3p24 in esophageal squamous cell carcinoma , 2009, Oncogene.

[55]  R. Medzhitov,et al.  Control of Inducible Gene Expression by Signal-Dependent Transcriptional Elongation , 2009, Cell.

[56]  M. Itokawa,et al.  Involvement of SMARCA2/BRM in the SWI/SNF chromatin-remodeling complex in schizophrenia. , 2009, Human molecular genetics.

[57]  Joseph T. Glessner,et al.  Genome wide association (GWA) predictors of anti‐TNF&agr; therapeutic responsiveness in pediatric inflammatory bowel disease , 2009, Inflammatory bowel diseases.

[58]  V. Lafont,et al.  The IFNgamma-induced STAT1-CBP/P300 association, required for a normal response to the cytokine, is disrupted in Brucella-infected macrophages. , 2009, Microbial pathogenesis.

[59]  Ming-Ming Zhou,et al.  Brd4 Coactivates Transcriptional Activation of NF-κB via Specific Binding to Acetylated RelA , 2008, Molecular and Cellular Biology.

[60]  Archana Dhasarathy,et al.  The MBD protein family-reading an epigenetic mark? , 2008, Mutation research.

[61]  E. Benveniste,et al.  Transcriptional activation of human matrix metalloproteinase-9 gene expression by multiple co-activators. , 2008, Journal of molecular biology.

[62]  A. Brasier,et al.  The STAT3 NH2-terminal Domain Stabilizes Enhanceosome Assembly by Interacting with the p300 Bromodomain* , 2008, Journal of Biological Chemistry.

[63]  Guy Pratt,et al.  A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia , 2008, Nature Genetics.

[64]  Ming-Ming Zhou,et al.  Structural insights into human KAP1 PHD finger–bromodomain and its role in gene silencing , 2008, Nature Structural &Molecular Biology.

[65]  H. Szerlong,et al.  The HSA domain binds nuclear actin-related proteins to regulate chromatin-remodeling ATPases , 2008, Nature Structural &Molecular Biology.

[66]  Q. Lu,et al.  Abnormal histone modification patterns in lupus CD4+ T cells. , 2008, The Journal of rheumatology.

[67]  H. Hibshoosh,et al.  BAF180 is a critical regulator of p21 induction and a tumor suppressor mutated in breast cancer. , 2008, Cancer research.

[68]  D. Steinemann,et al.  Gene expression profiling in hepatocellular carcinoma: upregulation of genes in amplified chromosome regions , 2008, Modern Pathology.

[69]  Thomas Walz,et al.  Role of the conserved Sir3-BAH domain in nucleosome binding and silent chromatin assembly. , 2007, Molecular cell.

[70]  Wolfgang Fischle,et al.  Structural basis for lower lysine methylation state-specific readout by MBT repeats of L3MBTL1 and an engineered PHD finger. , 2007, Molecular cell.

[71]  Yi Zhang,et al.  New Nomenclature for Chromatin-Modifying Enzymes , 2007, Cell.

[72]  M. Dietel,et al.  A snapshot of microarray-generated gene expression signatures associated with ovarian carcinoma , 2007, International Journal of Gynecologic Cancer.

[73]  S. Mujtaba,et al.  Structure and acetyl-lysine recognition of the bromodomain , 2007, Oncogene.

[74]  D. Peters,et al.  Rubinstein–Taybi syndrome: clinical and molecular overview , 2007, Expert Reviews in Molecular Medicine.

[75]  K. Friend,et al.  Mutations in the BRWD3 gene cause X-linked mental retardation associated with macrocephaly. , 2007, American journal of human genetics.

[76]  M. Duvic,et al.  Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma , 2007, Expert opinion on investigational drugs.

[77]  F. DeMayo,et al.  Achaete-scute homolog-1 linked to remodeling and preneoplasia of pulmonary epithelium , 2007, Laboratory Investigation.

[78]  F. Recillas-Targa,et al.  Expression of PCAF, p300 and Gcn5 and more highly acetylated histone H4 in pediatric tumors. , 2007, Journal of experimental & clinical cancer research : CR.

[79]  Jerry L. Workman,et al.  Histone acetyltransferase complexes: one size doesn't fit all , 2007, Nature Reviews Molecular Cell Biology.

[80]  K. Basso,et al.  Gene dosage alterations revealed by cDNA microarray analysis in cervical cancer: Identification of candidate amplified and overexpressed genes , 2007, Genes, chromosomes & cancer.

[81]  Katsuhito Yasuno,et al.  Reduced neuron-specific expression of the TAF1 gene is associated with X-linked dystonia-parkinsonism. , 2007, American journal of human genetics.

[82]  T. Kouzarides.  Chromatin Modifications and Their Function , 2007, Cell.

[83]  John D Aitchison,et al.  Yng1 PHD finger binding to H3 trimethylated at K4 promotes NuA3 HAT activity at K14 of H3 and transcription at a subset of targeted ORFs. , 2006, Molecular cell.

[84]  D. Blackwood,et al.  Evidence implicating BRD1 with brain development and susceptibility to both schizophrenia and bipolar affective disorder , 2006, Molecular Psychiatry.

[85]  Tad A. Holak,et al.  DNA-binding properties of the recombinant high-mobility-group-like AT-hook-containing region from human BRG1 protein , 2006, Biological chemistry.

[86]  D. Patel,et al.  Molecular basis for site-specific read-out of histone H3K4me3 by the BPTF PHD finger of NURF , 2006, Nature.

[87]  G. Sirugo,et al.  Variants in the SP110 gene are associated with genetic susceptibility to tuberculosis in West Africa , 2006, Proceedings of the National Academy of Sciences.

[88]  J. Ziegler,et al.  Mutations in the gene encoding the PML nuclear body protein Sp110 are associated with immunodeficiency and hepatic veno-occlusive disease , 2006, Nature Genetics.

[89]  S. Niemann,et al.  No associations of human pulmonary tuberculosis with Sp110 variants , 2005, Journal of Medical Genetics.

[90]  David S. Park,et al.  Apical role for BRG1 in cytokine-induced promoter assembly. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[91]  Johan T den Dunnen,et al.  Genetic heterogeneity in Rubinstein-Taybi syndrome: mutations in both the CBP and EP300 genes cause disease. , 2005, American journal of human genetics.

[92]  H. Dyson,et al.  Intrinsically unstructured proteins and their functions , 2005, Nature Reviews Molecular Cell Biology.

[93]  Ming-Ming Zhou,et al.  Selective small molecules blocking HIV-1 Tat and coactivator PCAF association. , 2005, Journal of the American Chemical Society.

[94]  H. Döhner,et al.  Translocation t(X;11)(q13;q23) in B‐cell chronic lymphocytic leukemia disrupts two novel genes , 2005, Genes, chromosomes & cancer.

[95]  M. Cleary,et al.  Binding to Nonmethylated CpG DNA Is Essential for Target Recognition, Transactivation, and Myeloid Transformation by an MLL Oncoprotein , 2004, Molecular and Cellular Biology.

[96]  C. Antonescu,et al.  Midline carcinoma of children and young adults with NUT rearrangement. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[97]  A. Jeltsch,et al.  Chromatin Targeting of de Novo DNA Methyltransferases by the PWWP Domain* , 2004, Journal of Biological Chemistry.

[98]  M. Vihinen,et al.  APECED‐causing mutations in AIRE reveal the functional domains of the protein , 2004, Human mutation.

[99]  Y. Kanno,et al.  Selective recognition of acetylated histones by bromodomain proteins visualized in living cells. , 2004, Molecular cell.

[100]  O. Evgrafov,et al.  BRD2 (RING3) is a probable major susceptibility gene for common juvenile myoclonic epilepsy. , 2003, American journal of human genetics.

[101]  Weidong Wang,et al.  Loss of BRG1/BRM in human lung cancer cell lines and primary lung cancers: correlation with poor prognosis. , 2003, Cancer research.

[102]  J. Fletcher,et al.  BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma. , 2003, Cancer research.

[103]  P. D. Dal Cin,et al.  BRD4 bromodomain gene rearrangement in aggressive carcinoma with translocation t(15;19). , 2001, The American journal of pathology.

[104]  C. Allis,et al.  Translating the Histone Code , 2001, Science.

[105]  T. Gibson,et al.  The SAND domain structure defines a novel DNA-binding fold in transcriptional regulation , 2001, Nature Structural Biology.

[106]  L. Etkin,et al.  Two B or not two B? Overview of the rapidly expanding B-box family of proteins. , 2001, Differentiation; research in biological diversity.

[107]  R. Copley,et al.  DDT -- a novel domain in different transcription and chromosome remodeling factors. , 2001, Trends in biochemical sciences.

[108]  H. Meyerson,et al.  Rubinstein–Taybi syndrome with humoral and cellular defects: a case report , 2000, Archives of disease in childhood.

[109]  J. Chiche,et al.  Sp110 Localizes to the PML-Sp100 Nuclear Body and May Function as a Nuclear Hormone Receptor Transcriptional Coactivator , 2000, Molecular and Cellular Biology.

[110]  Tony Kouzarides,et al.  Acetylation: a regulatory modification to rival phosphorylation? , 2000, The EMBO journal.

[111]  Carlos Caldas,et al.  Mutations truncating the EP300 acetylase in human cancers , 2000, Nature Genetics.

[112]  C. Allis,et al.  The language of covalent histone modifications , 2000, Nature.

[113]  N. Reich,et al.  Cooperation of the transcriptional coactivators CBP and p300 with Stat6. , 1999, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[114]  I. Wang,et al.  The Histone Acetylase PCAF Is a Phorbol-Ester-Inducible Coactivator of the IRF Family That Confers Enhanced Interferon Responsiveness , 1999, Molecular and Cellular Biology.

[115]  D. Housman,et al.  MLL is fused to CBP, a histone acetyltransferase, in therapy-related acute myeloid leukemia with a t(11;16)(q23;p13.3). , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[116]  F. Behm,et al.  All patients with the T(11;16)(q23;p13.3) that involves MLL and CBP have treatment-related hematologic disorders. , 1997, Blood.

[117]  S. M. de la Monte,et al.  Identification and Characterization of a Leukocyte-specific Component of the Nuclear Body* , 1996, The Journal of Biological Chemistry.

[118]  L. Staudt,et al.  LYSP100-associated nuclear domains (LANDs): description of a new class of subnuclear structures and their relationship to PML nuclear bodies. , 1996, Blood.

[119]  T. Iwama,et al.  p300 gene alterations in colorectal and gastric carcinomas. , 1996, Oncogene.

[120]  Raman Nambudripad,et al.  The ancient regulatory-protein family of WD-repeat proteins , 1994, Nature.

[121]  N. LeBrasseur,et al.  Brd2 disruption in mice causes severe obesity without Type 2 diabetes. , 2009, The Biochemical journal.

[122]  Christian Gieger,et al.  Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts , 2009, Nature Genetics.

[123]  J. Manfredi,et al.  Target structure-based discovery of small molecules that block human p53 and CREB binding protein association. , 2006, Chemistry & biology.